These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 28858439)

  • 1. Adherence to infliximab therapy in inflammatory bowel disease patients in a real-life setting.
    Martelli L; Lopez A; Strobel S; Danese S; Roblin X; Baumann C; Peyrin-Biroulet L
    J Dig Dis; 2017 Oct; 18(10):566-573. PubMed ID: 28858439
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
    Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
    Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dosing interval and diagnosis predict infliximab levels in patients with inflammatory bowel disease on maintenance treatment.
    Krajcovicova A; Batovsky M; Gregus M; Hlista M; Durina J; Leskova Z; Sturdik I; Gojdic M; Jalali Y; Koller T; Toth J; Huorka M; Hlavaty T
    Acta Gastroenterol Belg; 2018; 81(4):465-470. PubMed ID: 30645913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab.
    Orfanoudaki E; Gazouli M; Foteinogiannopoulou K; Theodoraki E; Legaki E; Romanos I; Mouzas I; Koutroubakis IE
    Eur J Gastroenterol Hepatol; 2019 Feb; 31(2):187-191. PubMed ID: 30543573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.
    Murthy SK; Greenberg GR; Croitoru K; Nguyen GC; Silverberg MS; Steinhart AH
    Inflamm Bowel Dis; 2015 Sep; 21(9):2090-6. PubMed ID: 26099066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications.
    Kunitake H; Hodin R; Shellito PC; Sands BE; Korzenik J; Bordeianou L
    J Gastrointest Surg; 2008 Oct; 12(10):1730-6; discussion 1736-7. PubMed ID: 18709514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adequate Infliximab Exposure During Induction Predicts Remission in Paediatric Patients With Inflammatory Bowel Disease.
    van Hoeve K; Dreesen E; Hoffman I; Van Assche G; Ferrante M; Gils A; Vermeire S
    J Pediatr Gastroenterol Nutr; 2019 Jun; 68(6):847-853. PubMed ID: 30633108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.
    Kevans D; Murthy S; Mould DR; Silverberg MS
    J Crohns Colitis; 2018 May; 12(6):662-669. PubMed ID: 29659758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An Increased Serum N-Terminal Telopeptide of Type I Collagen, a Biochemical Marker of Increased Bone Resorption, Is Associated with Infliximab Therapy in Patients with Crohn's Disease.
    Sugimoto K; Ikeya K; Iida T; Kawasaki S; Arai O; Umehara K; Watanabe F; Tani S; Oishi S; Osawa S; Yamamoto T; Hanai H
    Dig Dis Sci; 2016 Jan; 61(1):99-106. PubMed ID: 26254083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Predictors of Future Nonadherence in Inflammatory Bowel Disease.
    Severs M; Mangen MJ; Fidder HH; van der Valk ME; van der Have M; van Bodegraven AA; Clemens CHM; Dijkstra G; Jansen JM; de Jong DJ; Mahmmod N; van de Meeberg PC; van der Meulen-de Jong AE; Pierik M; Ponsioen CY; Romberg-Camps MJL; Siersema PD; Jharap B; van der Woude JC; Zuithoff NPA; Oldenburg B
    Inflamm Bowel Dis; 2017 Sep; 23(9):1568-1576. PubMed ID: 28700534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing Infliximab Prescription Patterns in Inflammatory Bowel Disease: A Population-Based Cohort Study, 1999-2014.
    Larsen L; Drewes AM; Broberg MCH; Fallingborg J; Jacobsen BA; Jensen TB; Jess T
    Inflamm Bowel Dis; 2018 Jan; 24(2):433-439. PubMed ID: 29361095
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study.
    Warman A; Straathof JW; Derijks LJ
    Eur J Gastroenterol Hepatol; 2015 Mar; 27(3):242-8. PubMed ID: 25569569
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment Persistence for Infliximab Versus Adalimumab in Crohn's Disease: A 14-Year Single-Center Experience.
    Olivera P; Thiriet L; Luc A; Baumann C; Danese S; Peyrin-Biroulet L
    Inflamm Bowel Dis; 2017 Jun; 23(6):976-985. PubMed ID: 28333755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
    Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
    Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.
    Filippi J; Laharie D; Michiels C; Flamand M; Bouguen G; Nancey S; Presles E; Paul S; Schneider S; Hébuterne X; Roblin X
    J Crohns Colitis; 2015 Mar; 9(3):252-8. PubMed ID: 25588386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy.
    Sokol H; Seksik P; Carrat F; Nion-Larmurier I; Vienne A; Beaugerie L; Cosnes J
    Gut; 2010 Oct; 59(10):1363-8. PubMed ID: 20587545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to Infliximab Treatment in a Pediatric Inflammatory Bowel Disease Cohort.
    Vitale DS; Greenley RN; Lerner DG; Mavis AM; Werlin SL
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):408-10. PubMed ID: 25885878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postoperative therapy with infliximab for Crohn's disease: a 2-year prospective randomized multicenter study in Japan.
    Fukushima K; Sugita A; Futami K; Takahashi KI; Motoya S; Kimura H; Yoshikawa S; Kinouchi Y; Iijima H; Endo K; Hibi T; Watanabe M; Sasaki I; Suzuki Y;
    Surg Today; 2018 Jun; 48(6):584-590. PubMed ID: 29383596
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Optimizing effect of infliximab upon inflammatory bowel disease].
    Li SR; Sheng JQ; Li SJ; Zhao XJ
    Zhonghua Yi Xue Za Zhi; 2009 Sep; 89(36):2568-70. PubMed ID: 20137621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does infliximab short infusion have a beneficial impact on the quality of life in patients with inflammatory bowel diseases? A single centre prospective evaluation.
    Principi M; Losurdo G; La Fortezza RF; Lopolito P; Lovero R; Grillo S; Bringiotti R; Ierardi E; Di Leo A
    J Gastrointestin Liver Dis; 2015 Jun; 24(2):165-70. PubMed ID: 26114175
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.